No Data
The Concept of Innovative Drugs mostly rose, with Shengnuo Pharmaceutical (02257) increasing by 11.56%. Institutions indicate that pharmaceutical innovation is the core driving force of pharmaceutical growth.
Jinwu Finance | Most Innovative Drug Concepts have risen, with Saint Nutra Pharma (02257) up 11.56%, Baiao Saitu (02315) up 9.68%, Geli Pharma (01672) up 7.98%, Lvzhu Bio (02480) up 4.73%, ZAI LAB (09688) up 4.41%, Connaught (02162) up 1.34%, SINO BIOPHARM (01177) up 0.95%, INNOVENT BIO (01801) up 0.69%. Galaxy Securities stated that 1) pharmaceutical innovation is the core driving force of pharmaceutical growth. Innovative drugs have transitioned from Me-too to
BioNTech announced that Adcendo ApS is exercising its antibody option to accelerate ADC development.
Adcendo exercises its options to further expand its ADC pipeline using Baiaosaitu's fully human antibodies, developing new therapies for cancers with high unmet Medical needs. This collaboration further validates the potential of Baiaosaitu's independently developed RenMice antibody discovery platform in promoting innovative therapies to benefit patients. Peking, December 16, 2024 /PR Newswire/ -- Baiaosaitu (Peking) Pharmaceutical Technology Co., Ltd. (Baiaosaitu, stock code: 02315.HK), an international Biotechnology company focused on the development of novel antibody/ADC therapies, announces.
Express News | Biocytogen Announces Adcendo Aps Exercises Antibody Option to Accelerate ADC Development
Gelonghui Announcement Highlights (Hong Kong Stocks) | Leapmotor (09863.HK) third-quarter revenue increased by 74.3% year-on-year to 9.86 billion yuan, expected to exceed the annual gross margin target.
【Today's Focus】Leapmotor (09863.HK) third-quarter revenue increased by 74.3% year-on-year to 9.86 billion yuan. Expected to exceed the annual gross margin target Leapmotor (09863.HK) announced that in the third quarter of 2024, the company's revenue was 9.86 billion yuan, an 83.9% increase from the second quarter, a 74.3% increase from 2023, mainly due to the significant increase in product delivery volume and optimization of product sales structure. The gross margin in the third quarter of 2024 was 8.1%, a significant improvement from 2.8% in the second quarter of 2024.
Express News | Biocytogen Announces Ideaya’s Nomination of Development Candidate Ide034, a Potential First-in-Class B7H3/Ptk7 Topo-I-Payload Bispecific ADC and Option Exercise
BeiGene-Bei (02315.HK): IDEAYA nominates B7H3/PTK7 dual-specific ADC with first-in-class potential as a development candidate drug and exercises the right of selection in parallel.
Grallhu November 11th | Beiou Sai Tu-B (02315.HK) announced that IDEAYA Biosciences, Inc. (nasdaq: IDYA) (IDEAYA), a precision medical company dedicated to the discovery and development of targeted therapeutic drugs for tumors, has exercised its option to obtain the global exclusive license for B7H3/PTK7 topoisomerase inhibitor payload dual-specific antibody-drug conjugate (BsADC) BCG034 (IDE034) with similar first-in-class potential as Beiou Sai Tu, and nominated the project as a development candidate drug.
meowmeow66 : I dont think moomoo can order this IPO. you can ask customer service to double check.